Gemma Salvadó
@gesalbla
Followers
2K
Following
6K
Media
102
Statuses
878
Leader of the Neuroimaging group at @BarcelonaBeta & @fpmaragall / Associate researcher at @biofinder_study, Lund University #Alzheimer #biomarkers
Joined September 2017
Happy to see this massive collaboration out covering 12 different cohorts including almost 3,000 cognitively unimpaired individuals. Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET
🚨Paper alert🚨 New publication in @JAMANeuro led by @gesalbla. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer's disease in cognitively unimpaired individuals. https://t.co/CLCtGxkV2P A 🧵...
2
4
12
Moments com els d'avui a la trobada anual de la @fpmaragall, amb testimonis tant potents com el de l'Isabel, ens ajuden a recordar que la ciència que fem és per tots ells. Participants, socis, voluntaris, malalts i cuidadors. I sobretot, per aconseguir un futur sense #Alzheimer
@ANavarroFPM @jaumecollboni @DrMacip @BarcelonaBeta @angelfont @CaixaResearch @FundlaCaixaCAT @recercauniscat @nmontlab @albertodepazmo La neuropsicòloga i coordinadora d'intervenció i capacitació de l'Àrea Social de la Fundació, Glòria Mas, i l’Isabel, recentment diagnosticada d’Alzheimer i participant del programa Plenament Actives, comparteix el seu testimoni. 💬
0
0
4
De camino a Sevilla para la #RASEN25 donde presentaré un trabajo de la @BarcelonaBeta investigando los niveles sutiles de amiloide y sus posibles implicaciones para ensayos clínicos y tratamientos.
0
0
3
Can we stage Alzheimer’s disease biologically using blood tau biomarkers? 🩸 Check out our new research briefing on this topic in @NatureAging, in collaboration with @gesalbla! https://t.co/HZRZNr3j1g
1
1
7
Karlsson et al. show that normalizing AD CSF and plasma biomarkers to reference proteins increases their agreement with tau- and amyloid PET, enhancing the accuracy of fluid biomarker tests for detecting pathological changes. https://t.co/uAK0GB1W48
0
9
22
🚨New in Lancet Neurology: Autopsy study of aducanumab in #Alzheimer’s shows superficial cortical Aβ cleared, but deeper persists. ARIA showed inflammation+ microinfarcts in leptomeningeal/penetrating vessels. Some path is PET-invisible. @DrNeuroChic
https://t.co/gAStfXlsTX...
4
31
64
What a cool project. Congrats!
Do p-tau217 levels rise without amyloid or tau aggregates? 🐻 In our Acta Neuropathologica paper, we show that 🩸 p-tau217 increases ~300% during bear hibernation, while hibernating hamsters also show ⬆️ p-tau but no changes in MTBR tau. https://t.co/8QgRj9hfR9
1
0
4
🧠✨ Avui és el #DiaMundialDelAlzheimer i volem donar les gràcies a totes les persones que ens acompanyen en el camí cap a un futur sense Alzheimer. 💚
3
26
54
🚨Postdoc position open at @BarcelonaBeta🚨 We're looking someone to work on a project at the intersection of cardiovascular and neurodegenerative research 🫀🧠 Fully funded position!!! More details: https://t.co/WhjnOn5CtE Please share! #Alzheimer's #ENDALZ
0
2
4
Excited to share our review on the latest developments in neuroimaging in #Alzheimer’s disease . Great resource to be up to date!
🔥Recent advances in #neuroimaging of #Alzheimers disease🧠✨ https://t.co/BrKZqeFjTY ➡️ Resource for researchers & clinicians ➡️ ATNIV biomarkers, staging, connectomics &more ➡️ Plus: how are sex & country represented in first/last authorship? @NeuroimagingPIA
@alzdemjournals
2
4
10
A next-generation blood test may do more than diagnose Alzheimer’s—it could help doctors personalize treatment by revealing how far the disease has progressed. BrightFocus Alzheimer's Disease Research grant recipient, Dr. Gemma Salvadó, helped validate this promising new blood
0
5
17
New paper published today in @NatureAging! This one took some time but it's always a pleasure working hand in hand with @MontoliuGaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data. A 🧵 below. #ENDALZ
🚨New publication in @NatureAging🚨 Co-led between @MontoliuGaya and @gesalbla. We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages. https://t.co/L3ieR6wLrz 🧵
1
3
13
Super proud of @ncjwarmenhoven! She just nailed her first oral presentation at an international conference #AAIC2025🇨🇦
1
1
17
Today I will present our work titled: Biological staging of AD with the novel plasma eMTBR-tau243 and %p-tau217 🪧Insights into disease trajectory and biological staging of AD 🕑 2PM 📍 Room 105 (even if it's not in the app) Don't miss it, it will be a great session! #AAIC2025
1
1
22
Outstanding plenary presentation by @sylv_villeneuve today on preclinical #Alzheimer’s disease. Her comprehensive overview of biomarkers, risk factors, and clinical trials highlighted critical directions for the future of AD research. #AAIC2025
0
4
43
Powerful words from Cliff Jack as he accepted his lifetime achievement award. We must protect and carry forward our longitudinal cohorts as they are the key to unlocking the mysteries of #Alzheimer’s. #AAIC2025
1
5
34
What a plenary! Congratulations @EmmaCoomans for such a great presentation at #AIC today, summarising the main neuroimaging papers of the year. Very exciting way to start #AAIC2025 🇨🇦
0
4
24
Tau PET positivity in individuals (42 cohorts worldwide, N = 12,048) with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex @RikOssenkoppele, @OskarHansson9, @AlzheimerAms, @biofinder_study
https://t.co/8IROVZ15yT
nature.com
Nature Neuroscience - Ossenkoppele, Coomans and colleagues analyzed the tau PET data of 12,048 individuals from 42 cohorts worldwide. They found that age, amyloid-β status, presence of an APOE...
0
11
29
🚨 Heading to @EANM_NucMed meeting in Barcelona this fall? Don’t miss our special session on the future of PET imaging in the era of emerging Alzheimer’s disease treatments. Join the discussion on what’s next and why it matters #EANM2025 #Neuroimaging #Alzheimers
We have a date on October 7!🧠 We are organising the event "Clinical Use of PET in Alzheimer's Disease: Challenges & Opportunities". We'll bring together experts in the field of nuclear medicine and #Alzheimer's to explore the latest developments in PET imaging techniques.
0
2
12